Published in Br J Cancer on May 15, 2007
Environmental causes of esophageal cancer. Gastroenterol Clin North Am (2009) 2.80
The minimal incubation period from the onset of Barrett's oesophagus to symptomatic adenocarcinoma. Br J Cancer (2011) 0.87
Male predominance of upper gastrointestinal adenocarcinoma cannot be explained by differences in tobacco smoking in men versus women. Eur J Cancer (2010) 0.84
An age-period-cohort analysis of obesity and incident esophageal adenocarcinoma among white males. Dis Esophagus (2016) 0.76
Achieving long term survival in oesophagectomy patients aged over 75. Ann Med Surg (Lond) (2016) 0.75
Survival benefit of surgery to patients with esophageal squamous cell carcinoma. Sci Rep (2017) 0.75
Increased resection rates and survival among patients aged 75 years and older with esophageal cancer: a Dutch nationwide population-based study. World J Surg (2012) 0.75
Patient Selection for Oesophagectomy: Impact of Age and Comorbidities on Outcome. World J Surg (2015) 0.75
Models for temporal variation in cancer rates. I: Age-period and age-cohort models. Stat Med (1987) 6.46
Models for temporal variation in cancer rates. II: Age-period-cohort models. Stat Med (1987) 6.44
Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg (1998) 4.95
Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med (2005) 4.52
Demographic variations in the rising incidence of esophageal adenocarcinoma in white males. Cancer (2001) 3.02
Columnar-lined lower esophagus: an acquired lesion with malignant predisposition. Report on 140 cases of Barrett's esophagus with 12 adenocarcinomas. J Thorac Cardiovasc Surg (1975) 2.92
Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus. Gastroenterology (2002) 2.88
Abdominal obesity and the risk of Barrett's esophagus. Am J Gastroenterol (2005) 2.60
The role of tobacco, snuff and alcohol use in the aetiology of cancer of the oesophagus and gastric cardia. Int J Cancer (2000) 2.58
Oesophageal and gastric cardia adenocarcinomas: analysis of regional variation using the Cancer Incidence in Five Continents database. Int J Epidemiol (2001) 2.56
Helicobacter pylori and gastroesophageal reflux disease: the bug may not be all bad. Am J Gastroenterol (1998) 2.51
Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett's oesophagus: a prospective study. Lancet Oncol (2005) 2.40
Increasing incidence of Barrett's oesophagus in the general population. Gut (2005) 2.34
Adenocarcinoma complicating columnar epithelium-lined (Barrett's) esophagus. Am J Clin Pathol (1978) 2.13
Epidemiological differences between adenocarcinoma of the oesophagus and adenocarcinoma of the gastric cardia in the USA. Gut (2002) 1.84
Adenocarcinoma of the esophagus and Barrett's esophagus: a population-based study. Am J Gastroenterol (1999) 1.76
Helicobacter pylori and the birth cohort effect: evidence of a continuous decrease of infection rates in childhood. Am J Gastroenterol (1997) 1.62
Adenocarcinomas of the distal oesophagus and gastric cardia are one clinical entity. Rotterdam Oesophageal Tumour Study Group. Br J Surg (1999) 1.56
Role of Helicobacter pylori CagA+ strains and risk of adenocarcinoma of the stomach and esophagus. Int J Cancer (2003) 1.55
Selective inhibition of cyclooxygenase-2 suppresses growth and induces apoptosis in human esophageal adenocarcinoma cells. Cancer Res (2000) 1.51
Helicobacter pylori infection and risk of cardia cancer and non-cardia gastric cancer. A nested case-control study. Scand J Gastroenterol (1999) 1.45
The epidemic of esophageal adenocarcinoma. Gastroenterol Clin North Am (2002) 1.29
Concepts in the prevention of adenocarcinoma of the distal esophagus and proximal stomach. CA Cancer J Clin (2005) 1.22
Adenocarcinoma of the oesophagus and ectopic gastric mucosa. Br J Cancer (1952) 1.20
Long-term and recent time trends in the prevalence of obesity among Dutch men and women. Int J Obes Relat Metab Disord (2002) 1.15
Cancer of the gastric cardia. Best Pract Res Clin Gastroenterol (2006) 1.09
Rofecoxib inhibits cyclooxygenase 2 expression and activity and reduces cell proliferation in Barrett's esophagus. Gastroenterology (2002) 1.09
Daily use of non-steroidal anti-inflammatory drugs is less frequent in patients with Barrett's oesophagus who develop an oesophageal adenocarcinoma. Aliment Pharmacol Ther (2004) 1.05
When saliva meets acid: chemical warfare at the oesophagogastric junction. Gut (2005) 0.98
Heavy users of non-steroidal anti-inflammatory drugs: a nationwide prescription database study in Finland. Eur J Clin Pharmacol (2003) 0.94
Nonsteroidal anti-inflammatory drug use associated with reduced incidence of adenocarcinomas of the esophagus and gastric cardia that overexpress cyclin D1: a population-based study. Cancer Epidemiol Biomarkers Prev (2004) 0.94
The incidence of adenocarcinoma and squamous cell carcinoma of the esophagus: Barrett's esophagus makes a difference. Am J Gastroenterol (2005) 0.91
Nitrate and nitrosative chemistry within Barrett's oesophagus during acid reflux. Gut (2005) 0.89
The incidence of adenocarcinoma in Barrett's esophagus in an institutionalized population. Eur J Gastroenterol Hepatol (2004) 0.87
Mortality trend from cancer of the gastric cardia in The Netherlands, 1969-1994. Int J Epidemiol (1999) 0.87
Carcinogenesis at the gastroesophageal junction: free radicals at the frontier. Gastroenterology (2002) 0.86
Effect of chronic intake of NSAIDs and cyclooxygenase 2-selective inhibitors on esophageal cancer incidence. Clin Gastroenterol Hepatol (2004) 0.84
Use of nonsteroidal anti-inflammatory drugs and gastroprotective agents before the advent of cyclooxygenase-2-selective inhibitors: analysis of a large United States claims database. Clin Ther (2001) 0.83
Comparison of prevalence and resection rates in patients with esophageal squamous cell carcinoma and adenocarcinoma. J Thorac Cardiovasc Surg (1996) 0.83
Are carcinomas of the cardia oesophageal or gastric adenocarcinomas? Eur J Cancer (2003) 0.81
'Cardiac-type' (mucinous) mucosa and carditis are both associated with Helicobacter pylori-related gastritis. Eur J Gastroenterol Hepatol (2004) 0.80
Comparison of cohort smoking intensities in Denmark and the Netherlands. Bull World Health Organ (2002) 0.79
[Palliative treatment in patients with oesophagus carcinoma]. Ned Tijdschr Geneeskd (2005) 0.77
Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer (2013) 14.03
Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut (2006) 9.03
Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: results from a large population-based follow-up study. Diabetologia (2011) 3.52
[Occult blood studies of the feces obsolete]. Ned Tijdschr Geneeskd (1996) 3.29
Nurse endoscopists perform colonoscopies according to the international standard and with high patient satisfaction. Endoscopy (2012) 3.27
Helicobacter pylori eradication and gastric cancer: when is the horse out of the barn? Am J Gastroenterol (2009) 2.89
Effect of comorbidity on the treatment and prognosis of elderly patients with non-small cell lung cancer. Thorax (2004) 2.77
Potential role of molecular mimicry between Helicobacter pylori lipopolysaccharide and host Lewis blood group antigens in autoimmunity. Infect Immun (1996) 2.75
Colonoscopy perforation rate, mechanisms and outcome: from diagnostic to therapeutic colonoscopy. Endoscopy (2009) 2.70
Complications of single-balloon enteroscopy: a prospective evaluation of 166 procedures. Endoscopy (2010) 2.62
Short-term esophageal stenting in the management of benign perforations. Am J Gastroenterol (2010) 2.55
Double-balloon enteroscopy: indications, diagnostic yield, and complications in a series of 275 patients with suspected small-bowel disease. Endoscopy (2006) 2.43
Increasing incidence of Barrett's oesophagus in the general population. Gut (2005) 2.34
Helicobacter pylori and the efficacy of omeprazole therapy for gastroesophageal reflux disease. Am J Gastroenterol (1999) 2.33
High cancer risk in Peutz-Jeghers syndrome: a systematic review and surveillance recommendations. Am J Gastroenterol (2010) 2.32
Omeprazole as a diagnostic tool in gastroesophageal reflux disease. Am J Gastroenterol (1997) 2.17
[Guideline 'Melanoma' (3rd revision)]. Ned Tijdschr Geneeskd (2005) 2.08
The incidence of Barrett's oesophagus and oesophageal adenocarcinoma in the United Kingdom and The Netherlands is levelling off. Aliment Pharmacol Ther (2014) 2.07
[The practice guideline: 'Treatment of tobacco dependence']. Ned Tijdschr Geneeskd (2005) 2.06
The yield of first-time endoscopic ultrasonography in screening individuals at a high risk of developing pancreatic cancer. Am J Gastroenterol (2009) 2.04
[Acute dysphasia: often there is a readily treatable cause]. Ned Tijdschr Geneeskd (2003) 2.03
A comparison of 3 types of covered metal stents for the palliation of patients with dysphagia caused by esophagogastric carcinoma: a prospective, randomized study. Gastrointest Endosc (2001) 2.03
Risk of second primary in situ and invasive melanoma in a Dutch population-based cohort: 1989-2008. Br J Dermatol (2012) 2.03
Immunochemical fecal occult blood testing is equally sensitive for proximal and distal advanced neoplasia. Am J Gastroenterol (2012) 1.98
[Surgery and referral for subsequent 131I therapy for patients with differentiated thyroid carcinoma in the south-east of the Netherlands, 1983-1996, compared to the consensus guidelines from 1987]. Ned Tijdschr Geneeskd (2002) 1.94
On the rising trends of incidence and prognosis for breast cancer patients diagnosed 1975-2004: a long-term population-based study in southeastern Netherlands. Cancer Causes Control (2007) 1.93
Screening for colorectal cancer: random comparison of guaiac and immunochemical faecal occult blood testing at different cut-off levels. Br J Cancer (2009) 1.93
Less extensive treatment and inferior prognosis for breast cancer patient with comorbidity: a population-based study. Eur J Cancer (2005) 1.93
Determining the cause of death in randomized screening trial(s) for prostate cancer. BJU Int (2003) 1.90
Long-term esophageal cancer risk in patients with primary achalasia: a prospective study. Am J Gastroenterol (2010) 1.85
Systematic review: temporary stent placement for benign rupture or anastomotic leak of the oesophagus. Aliment Pharmacol Ther (2011) 1.85
Systematic review: the global incidence and prevalence of peptic ulcer disease. Aliment Pharmacol Ther (2009) 1.83
Optimal resource allocation in colonoscopy: timing of follow-up colonoscopies in relation to adenoma detection rates. Endoscopy (2013) 1.82
The detection, surveillance and treatment of premalignant gastric lesions related to Helicobacter pylori infection. Helicobacter (2007) 1.77
Prevalence of Helicobacter pylori resistance to metronidazole, clarithromycin, amoxycillin, tetracycline and trovafloxacin in The Netherlands. J Antimicrob Chemother (1999) 1.73
Helicobacter pylori: a true carcinogen? Eur J Gastroenterol Hepatol (1998) 1.72
Verapamil is associated with an increased risk of cancer in the elderly: the Rotterdam study. Eur J Cancer (2003) 1.70
Are patients with skin cancer at lower risk of developing colorectal or breast cancer? Am J Epidemiol (2008) 1.69
Staging investigations for oesophageal cancer: a meta-analysis. Br J Cancer (2008) 1.69
Time-trends in gastroprotection with nonsteroidal anti-inflammatory drugs (NSAIDs). Aliment Pharmacol Ther (2010) 1.68
Epidemiology of unknown primary tumours; incidence and population-based survival of 1285 patients in Southeast Netherlands, 1984-1992. Eur J Cancer (2002) 1.66
Predictions of skin cancer incidence in the Netherlands up to 2015. Br J Dermatol (2005) 1.66
Admission time is associated with outcome of upper gastrointestinal bleeding: results of a multicentre prospective cohort study. Aliment Pharmacol Ther (2012) 1.63
Parietal cell protrusions and fundic gland cysts during omeprazole maintenance treatment. Hum Pathol (2000) 1.62
Helicobacter pylori and the birth cohort effect: evidence of a continuous decrease of infection rates in childhood. Am J Gastroenterol (1997) 1.62
Hypergastrinaemia during long-term omeprazole therapy: influences of vagal nerve function, gastric emptying and Helicobacter pylori infection. Aliment Pharmacol Ther (1998) 1.61
Clinical outcome of progressive stenting in patients with anastomotic strictures after orthotopic liver transplantation. Endoscopy (2013) 1.61
Nickel-responsive induction of urease expression in Helicobacter pylori is mediated at the transcriptional level. Infect Immun (2001) 1.59
Systematic review: Rebound acid hypersecretion after therapy with proton pump inhibitors. Aliment Pharmacol Ther (2007) 1.59
Explaining the bias in the 23S rRNA gene mutations associated with clarithromycin resistance in clinical isolates of Helicobacter pylori. Antimicrob Agents Chemother (1998) 1.56
Prevalence of autoimmune pancreatitis and other benign disorders in pancreatoduodenectomy for presumed malignancy of the pancreatic head. Dig Dis Sci (2012) 1.56
Comparative genomic hybridisation. Mol Pathol (1999) 1.56
Adenocarcinomas of the distal oesophagus and gastric cardia are one clinical entity. Rotterdam Oesophageal Tumour Study Group. Br J Surg (1999) 1.56
Predictors of dose escalation of adalimumab in a prospective cohort of Crohn's disease patients. Aliment Pharmacol Ther (2011) 1.53
Proton pump inhibitor therapy predisposes to community-acquired Streptococcus pneumoniae pneumonia. Aliment Pharmacol Ther (2012) 1.53
Rapid quantitative assessment of gastric corpus atrophy in tissue sections. J Clin Pathol (2001) 1.50
[Palliative treatment of esophageal cancer with dysphagia: more favourable outcome from single-dose internal brachytherapy than from the placement of a self-expanding stent; a multicenter randomised study]. Ned Tijdschr Geneeskd (2005) 1.48
Sequential therapy; a new treatment for Helicobacter pylori infection. But is it ready for general use? Dig Liver Dis (2004) 1.47
Variations in treatment policies and outcome for bladder cancer in the Netherlands. Eur J Surg Oncol (2010) 1.47
Grading of dysplasia in Barrett's oesophagus: substantial interobserver variation between general and gastrointestinal pathologists. Histopathology (2007) 1.47
Prognosis for long-term survivors of cancer. Ann Oncol (2007) 1.47
The number of retrieved oocytes does not decrease during consecutive gonadotrophin-stimulated IVF cycles. Hum Reprod (2004) 1.46
Endoscopic ablation therapy for Barrett's esophagus with high-grade dysplasia: a review. Am J Gastroenterol (1999) 1.45
Prediction scores in gastrointestinal bleeding: a systematic review and quantitative appraisal. Endoscopy (2012) 1.45
European guidelines for quality assurance in colorectal cancer screening and diagnosis: overview and introduction to the full supplement publication. Endoscopy (2012) 1.44
[The correlation of age and comorbidity with therapy and survival in cancer patients in North-Brabant and North-Limburg, 1995-2001]. Ned Tijdschr Geneeskd (2005) 1.44
Comparison of magnetic resonance enteroclysis and capsule endoscopy with balloon-assisted enteroscopy in patients with obscure gastrointestinal bleeding. Endoscopy (2012) 1.44
Co-morbidity leads to altered treatment and worse survival of elderly patients with colorectal cancer. Br J Surg (2005) 1.44
The NordICC Study: rationale and design of a randomized trial on colonoscopy screening for colorectal cancer. Endoscopy (2012) 1.44
[Double-balloon enteroscopy of the small intestine]. Ned Tijdschr Geneeskd (2007) 1.43
Evaluation of reporting based on descriptional knowledge. J Am Med Inform Assoc (1996) 1.42
Single and repeated GnRH agonist stimulation tests compared with basal markers of ovarian reserve in the prediction of outcome in IVF. J Assist Reprod Genet (2005) 1.42
[Trends in the incidence and death from cancer from 1989-2003 in The Netherlands]. Ned Tijdschr Geneeskd (2006) 1.42
[Diagnosis and treatment of esophageal cancer in the Netherlands: wide variation in the second line]. Ned Tijdschr Geneeskd (2003) 1.40
Comparison of inter- and intra-cycle variability of anti-Mullerian hormone and antral follicle counts. Hum Reprod (2009) 1.40
Hemospray in the treatment of upper gastrointestinal hemorrhage in patients on antithrombotic therapy. Endoscopy (2012) 1.40
Helicobacter pylori, acid, and omeprazole revisited: bacterial eradication and rebound hypersecretion. Gastroenterology (1999) 1.40
Factors influencing the miss rate of polyps in a back-to-back colonoscopy study. Endoscopy (2012) 1.39
[Incidental cystic structures in the upper abdomen: to remove or not to remove?]. Ned Tijdschr Geneeskd (2006) 1.39
[A comparative study of the expenditures on health research in 7 western countries in 1997 places the Netherlands at the bottom of the list]. Ned Tijdschr Geneeskd (2002) 1.39
Multiplicity in polyp count and extracolonic manifestations in 40 Dutch patients with MYH associated polyposis coli (MAP). J Med Genet (2005) 1.38
Country-specific constancy by age in cagA+ proportion of Helicobacter pylori infections. Int J Cancer (1997) 1.38
[Gastrojejunostomy versus endoscopic stent placement as palliative treatment of malignant stenosis of the duodenum: overview of advantages and disadvantages on the basis of a literature study]. Ned Tijdschr Geneeskd (2007) 1.38
Cancer in children and adolescents in Europe: developments over 20 years and future challenges. Eur J Cancer (2006) 1.38
5-aminolevulinic acid photodynamic therapy versus argon plasma coagulation for ablation of Barrett's oesophagus: a randomised trial. Gut (2004) 1.37
Percutaneous endoscopic gastrostomy: complications and suggestions to avoid them. Eur J Gastroenterol Hepatol (2001) 1.37
Predictors for neoplastic progression in patients with Barrett's Esophagus: a prospective cohort study. Am J Gastroenterol (2011) 1.36